ICMR Study Links Carbapenem-Resistant Infections to Higher Mortality

A three-year ICMR study of 159,336 patients across 20 tertiary-care hospitals found that carbapenem drug-resistant infections significantly increase patient mortality and treatment costs.

Among patients with Gram-negative infections, over 60% were resistant to carbapenem antibiotics, with resistant E. coli and P. aeruginosa showing 41% and 43% higher relative risks of death, respectively.

Published in The Lancet Regional Health, the study highlights the urgent need for integrated surveillance linking antimicrobial resistance to clinical outcomes and improved infection prevention strategies.